<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461876</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00020911</org_study_id>
    <nct_id>NCT01461876</nct_id>
  </id_info>
  <brief_title>Obesity in HIV After Antiretroviral Therapy</brief_title>
  <official_title>Changes in Overweight/Obesity Status, hsCRP, and D-dimer in HIV-infected Patients After 12 Months of Initial Antiretroviral Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective longitudinal study that evaluates the prevalence and incidence of&#xD;
      overweight/obesity within an HIV-infected population before and after 12 and 24 months of a&#xD;
      stable antiretroviral therapy (ART). The study group will be compared to the weight of a&#xD;
      healthy, matched population that is not infected with HIV. The primary hypothesis states that&#xD;
      the proportion of HIV-infected persons newly classified as overweight/obese will increase by&#xD;
      ≥20% after 12 months of initial ART, and this incidence will be greater than that of a&#xD;
      matched HIV-uninfected control population. The effect of immune function variables, such as&#xD;
      CD4, HIV viral load, and ART regimen on weight will be analyzed. In addition, the study will&#xD;
      analyze the effect of weight and immune function markers on the inflammatory markers, high&#xD;
      sensitivity C-reactive protein (hsCRP) and D-dimer. An HIV samples repository will be used&#xD;
      for specimens to be assayed for hsCRP and D-dimer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BMI from baseline after 12 months of initial antiretroviral therapy</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the inflammatory marker, high-sensitivity C-reactive protein, from baseline after 12 months of antiretroviral therapy</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the prothrombotic marker, D-dimer, from baseline after 12 months of initial antiretroviral therapy</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>HIV-infected cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-uninfected control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiretroviral therapy</intervention_name>
    <description>Standard of care antiretroviral therapy</description>
    <arm_group_label>HIV-infected cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      These samples represent residual plasma retained after clinical testing (HIV RNA PCR) has&#xD;
      been completed. Since the samples were obtained as part of routine clinical care, they are&#xD;
      part of the HIV samples repository at Duke University Medical Center.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects (≥ 18 years of age) infected with HIV-1 treated in the Infectious Disease&#xD;
        Clinic at Duke University Medical Center between 3/1/98 to 3/1/08 who meet eligibility&#xD;
        criteria.&#xD;
&#xD;
        Adult subjects (≥ 18 years of age), followed in primary care clinics within the Duke Health&#xD;
        System between 3/1/98 to 3/1/08, who meet eligibility criteria. Control subjects must have&#xD;
        data for weight 12 months after baseline visit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria for HIV-infected cohort:&#xD;
&#xD;
               1. Treatment-naive at study entry;&#xD;
&#xD;
               2. Subjects will need to remain on ART for 12 months as initiated with substitution&#xD;
                  allowed for toxicity management within the same class of drug;&#xD;
&#xD;
               3. Subjects within this group that remain on ART for an additional 12 months (total&#xD;
                  24 months) as initiated with substitution allowed for toxicity management within&#xD;
                  the same class of drug will continue to be followed longitudinally for the 24&#xD;
                  month period;&#xD;
&#xD;
               4. Availability of repository samples.&#xD;
&#xD;
                  Inclusion Criteria for Control Cohort:&#xD;
&#xD;
                  Followed in the Duke Primary Care Clinics during the years of inclusion with&#xD;
                  available data on weight, race and gender.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria for HIV-infected cohort:&#xD;
&#xD;
          1. Pregnancy during period of observation or within 6 months of study entry;&#xD;
&#xD;
          2. Malignancy (other than squamous or basal cell carcinomas of the skin);&#xD;
&#xD;
          3. Newly diagnosed thyroid disorder within 6 months of study entry;&#xD;
&#xD;
          4. Use of megace or marinol;&#xD;
&#xD;
          5. Long-term use of glucocorticoids (greater than 1 month of prednisone 5mg or higher or&#xD;
             an equivalent dose of another glucocorticoid);&#xD;
&#xD;
          6. Use of androgenic steroids;&#xD;
&#xD;
          7. History of diabetes or use of glucose-lowering agents;&#xD;
&#xD;
          8. Use of the following psychiatric or anticonvulsant agents- thioridazine, olanzapine&#xD;
             (zyprexa), clozapine (clozaril), quetiapine (seroquel), risperidone (risperdal),&#xD;
             lithium, remeron, paxil, valproate, carbamazepine, gabapentin;&#xD;
&#xD;
          9. Concurrent treatment for hepatitis C infection;&#xD;
&#xD;
         10. Diagnosis of a new opportunistic infection (OI) as defined by the CDC during the 1st&#xD;
             12 months of ART.22 OIs include the following: PCP, toxoplasmosis, MAC,&#xD;
             histoplasmosis, candidiasis, cryptococcus, coccidiodes, CMV, cryptosporidium,&#xD;
             microsporidiosis, tuberculosis, bartonellosis, herpes simplex virus, HHV-8, human&#xD;
             papillomavirus;&#xD;
&#xD;
         11. Diagnosis of congestive heart failure and receiving diuretic therapy;&#xD;
&#xD;
         12. End stage renal disease.&#xD;
&#xD;
        Exclusion Criteria for Control Cohort:&#xD;
&#xD;
          1. Pregnancy during period of observation or within 6 months of study entry;&#xD;
&#xD;
          2. Malignancy (other than squamous or basal cell carcinomas of the skin);&#xD;
&#xD;
          3. Newly diagnosed thyroid disorder within 6 months of study entry;&#xD;
&#xD;
          4. Long-term use of glucocorticoids (greater than 1 month of prednisone 5mg or higher or&#xD;
             an equivalent dose of another glucocorticoid);&#xD;
&#xD;
          5. Use of androgenic steroids;&#xD;
&#xD;
          6. History of diabetes or use of glucose-lowering agents;&#xD;
&#xD;
          7. Use of the following psychiatric or anticonvulsant agents- thioridazine, olanzapine&#xD;
             (zyprexa), clozapine (clozaril), quetiapine (seroquel), risperidone (risperdal),&#xD;
             lithium, remeron, paxil, valproate, carbamazepine, gabapentin;&#xD;
&#xD;
          8. Treatment for hepatitis C infection during observation period;&#xD;
&#xD;
          9. Diagnosis of congestive heart failure and receiving diuretic therapy;&#xD;
&#xD;
         10. End stage renal disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanda Lakey, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>October 11, 2015</last_update_submitted>
  <last_update_submitted_qc>October 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

